Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL - Summary - MDSpire
From the Journals

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

  • By

  • Matthew Stenger

  • May 5, 2026

  • 2 min

Share

A study published in the Journal of Clinical Oncology by Uppal et al. examined TP53 mutations in patients with diffuse large B-cell lymphoma (DLBCL). Analyzing data from 3,091 patients across ten cohorts, the study found TP53 mutations significantly impact prognosis, with variant allele frequency (VAF) as a key determinant of outcomes. The presence of TP53 mutations correlated with poor progression-free and overall survival, which were enhanced by adding ibrutinib to R-CHOP therapy. The findings indicate that prognosis varies based on intrinsic genetic factors and environmental influences.

Original Source(s)

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

  • by Matthew Stenger

  • May 5, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min